Aurinia Pharmaceuticals (AUPH) Stock
Kidney disease biotech with approved lupus therapy. Here's the price, business snapshot, and what's worth knowing about Aurinia Pharmaceuticals in August 2026.
Aurinia Pharmaceuticals (AUPH) is a clinical-stage biotechnology company focused on therapies for autoimmune and inflammatory kidney disorders. Its lead product, voclosporin (marketed as Lupkynis), targets lupus nephritis and represents the company’s primary commercial revenue driver following regulatory approvals. Investors should watch sales uptake, pricing and reimbursement decisions, and the company’s ability to expand indications or develop next-generation candidates. Financially, Aurinia is a smaller-cap biopharma (market capitalisation around $1.56bn) so trading can be volatile and dependent on clinical data, regulatory milestones and partnering activity. Key risks include competitive treatments, uncertain long-term commercial adoption, regulatory hurdles and the typical clinical development risks. This summary is for general educational purposes only and not personalised investment advice; potential investors should consider their objectives and seek independent advice before investing.
Sixth Month Growth Performance
Stock Performance Snapshot
Financial Health
Aurinia Pharmaceuticals shows strong revenue and profit margins, indicating solid financial performance.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Approved therapy traction
Voclosporin’s commercial uptake is central to Aurinia’s near-term outlook; sales and reimbursement trends are worth watching, though outcomes can vary.
Pipeline and expansion
Clinical studies and potential label expansions could meaningfully change prospects, but development and regulatory risks remain.
Market and competition
Competitive immunosuppressants and payer decisions influence long-term adoption; investors should balance opportunity with typical biotech volatility.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
